查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595114

骨关节炎疼痛治疗药物市场：依药物类别、给药途径、通路 - 全球预测 2025-2030

Osteoarthritis Pain Drug Market by Drug Class (Corticosteriods, NSAIDs, Viscosupplementation), Route of Administration (Oral, Parenteral, Topical), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年骨关节炎止痛药市值为80.3亿美元，预计2024年将达到85.4亿美元，复合年增长率为6.47%，到2030年将达到12.4亿美元，预计将达到7000万美元。

骨关节炎止痛药物市场包括为缓解骨关节炎（一种老年人常见的退化性关节疾病）相关疼痛而开发的药物。该市场包括不同类型的药物，如非类固醇消炎剂(NSAID)、镇痛药、COX-2 抑制剂和皮质类固醇。由于世界人口老化、肥胖率增加以及生活方式的改变增加了关节退化的风险，骨关节炎的盛行率不断增加，推动了对这些药物的需求。骨关节炎的慢性、通常使人衰弱的性质强调了对骨关节炎止痛药的需求，这对生活品质有重大影响。它们的开发对医疗保健至关重要，因为这些药物的用途不仅限于缓解疼痛，还包括改善活动能力和整体功能。最终用途主要包括医院、诊所和家庭护理场所。关键的成长要素包括药物传输系统的进步以及对副作用最小的有效治疗方法的研发投资的增加。个人化医疗和生物製药的兴起带来了潜在的机会，向医疗保健基础设施不断改善的新兴市场的扩张也带来了潜在的机会。然而，挑战包括严格的监管核准、长期使用这些药物的潜在副作用以及物理疗法和营养食品等替代疗法的竞争。此外，高昂的药品成本和报销问题可能会限制可及性和市场扩张。业务成长需要将创新重点放在开发具有新颖作用机制、改善安全性和提高功效的药物。探索生物标记还可以实现更有针对性的治疗方法并提高竞争力。市场竞争激烈，各大公司在研发方面投入巨资，以维持和扩大市场占有率。整体而言，市场格局提供了巨大的成长潜力，但必须策略性地驾驭监管和竞争格局。

主要市场统计
基准年[2023] 80.3亿美元
预测年份 [2024] 85.4亿美元
预测年份 [2030] 124.7亿美元
复合年增长率（%） 6.47%

市场动态：快速发展的骨关节炎疼痛治疗市场的关键市场洞察

骨关节炎止痛药市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 骨关节炎盛行率不断增加，易患骨关节炎的人不断增加
    • 运动伤害增加
    • 提高消费者意识层级并改进技术
  • 市场限制因素
    • 药物研发高成本、副作用严重
  • 市场机会
    • 医疗保健和製药领域的进步
    • 持续研发
    • 政府与私人公司在药品供应上建立伙伴关係
  • 市场挑战
    • 存在假冒和廉价药品

波特五力：开拓骨关节炎疼痛治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解骨关节炎疼痛治疗市场的外部影响

外部宏观环境因素在塑造骨关节炎疼痛治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解骨关节炎疼痛治疗药物市场的竞争状况

对骨关节炎疼痛治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵骨关节炎疼痛治疗药物市场供应商的绩效评估

FPNV 定位矩阵是评估骨关节炎疼痛治疗药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划骨关节炎疼痛治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对骨关节炎疼痛治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 骨关节炎盛行率不断增加，易患骨关节炎的人不断增加
      • 运动伤害增加
      • 提高消费者意识层级并改进技术
    • 抑制因素
      • 药物研发高成本、副作用严重
    • 机会
      • 医疗保健和製药领域的进步
      • 持续研究与开发
      • 政府与私人公司在药品供应上的合作
    • 任务
      • 存在假冒和廉价药品
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章骨关节炎疼痛治疗药物市场（依药物类别）

  • 皮质类固醇
  • NSAIDs
  • 关节内粘稠补充疗法

第七章骨关节炎疼痛治疗市场：依给药途径

  • 口服
  • 胃肠外的
  • 话题

第八章骨关节炎疼痛治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章北美和南美的骨关节炎疼痛治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太骨关节炎疼痛治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的骨关节炎疼痛治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Abiogen Pharma Spa
  • Bayer AG
  • Bioventus
  • Eli Lilly and Company
  • Ferring BV
  • GlaxoSmithKline Plc.
  • Horizon Therapeutics plc
  • Johnson & Johnson Private Limited
  • Medivir AB
  • Merck Sharp & Dohme Corp.
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
Product Code: MRR-0376B2CAAFEB

The Osteoarthritis Pain Drug Market was valued at USD 8.03 billion in 2023, expected to reach USD 8.54 billion in 2024, and is projected to grow at a CAGR of 6.47%, to USD 12.47 billion by 2030.

The osteoarthritis pain drug market encompasses medications developed to alleviate pain associated with osteoarthritis, a degenerative joint disease commonly affecting the elderly. This market includes various drug types such as NSAIDs, analgesics, COX-2 inhibitors, and corticosteroids. The demand for these drugs is driven by the growing prevalence of osteoarthritis due to an aging global population, increasing obesity rates, and lifestyle changes that heighten the risk of joint degeneration. The necessity for osteoarthritis pain medication is underscored by the chronic and often debilitating nature of the condition, which significantly impacts the quality of life. Applications of these drugs extend beyond pain relief to improving mobility and overall function, making their development crucial for healthcare. End-use scope primarily includes hospitals, clinics, and home care settings. Key growth factors include advances in drug delivery systems and increased investment in research and development for effective therapies with minimal side effects. The rise of personalized medicine and biologic drugs presents potential opportunities, as does the expansion into emerging markets where healthcare infrastructure is improving. However, challenges include stringent regulatory approvals, potential side effects of long-term use of these drugs, and competition from alternative therapies like physical therapy and dietary supplements. Moreover, high drug costs and reimbursement issues can limit accessibility and market expansion. For business growth, innovation should focus on developing drugs with novel mechanisms of action, improved safety profiles, and enhanced efficacy. Exploring biomarkers for more tailored treatment approaches could also provide a competitive edge. The market is characterized by high competition, with major players investing heavily in R&D to maintain or augment their market share. Overall, the osteoarthritis pain drug market offers significant growth potential but requires strategic navigation of regulatory and competitive landscapes.

KEY MARKET STATISTICS
Base Year [2023] USD 8.03 billion
Estimated Year [2024] USD 8.54 billion
Forecast Year [2030] USD 12.47 billion
CAGR (%) 6.47%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Osteoarthritis Pain Drug Market

The Osteoarthritis Pain Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of osteoarthritis and growing population susceptible to osteoarthritis
    • Rising number of sports injuries
    • Increasing consumer awareness level and improved technology
  • Market Restraints
    • High cost of drug development and severe side-effects
  • Market Opportunities
    • Advancement in the healthcare and pharmaceutical sectors
    • Ongoing research and development
    • Collaborations between governments and private companies for the supply of drugs
  • Market Challenges
    • Presence of counterfeit and cheap quality drugs

Porter's Five Forces: A Strategic Tool for Navigating the Osteoarthritis Pain Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Osteoarthritis Pain Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Osteoarthritis Pain Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Osteoarthritis Pain Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Osteoarthritis Pain Drug Market

A detailed market share analysis in the Osteoarthritis Pain Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Osteoarthritis Pain Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Osteoarthritis Pain Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Osteoarthritis Pain Drug Market

A strategic analysis of the Osteoarthritis Pain Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Osteoarthritis Pain Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abiogen Pharma Spa, Bayer AG, Bioventus, Eli Lilly and Company, Ferring B.V., GlaxoSmithKline Plc., Horizon Therapeutics plc, Johnson & Johnson Private Limited, Medivir AB, Merck Sharp & Dohme Corp., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Osteoarthritis Pain Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Corticosteriods, NSAIDs, and Viscosupplementation.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of osteoarthritis and growing population susceptible to osteoarthritis
      • 5.1.1.2. Rising number of sports injuries
      • 5.1.1.3. Increasing consumer awareness level and improved technology
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of drug development and severe side-effects
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in the healthcare and pharmaceutical sectors
      • 5.1.3.2. Ongoing research and development
      • 5.1.3.3. Collaborations between governments and private companies for the supply of drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of counterfeit and cheap quality drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Osteoarthritis Pain Drug Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Corticosteriods
  • 6.3. NSAIDs
  • 6.4. Viscosupplementation

7. Osteoarthritis Pain Drug Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral
  • 7.4. Topical

8. Osteoarthritis Pain Drug Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Osteoarthritis Pain Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Osteoarthritis Pain Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Osteoarthritis Pain Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abiogen Pharma Spa
  • 3. Bayer AG
  • 4. Bioventus
  • 5. Eli Lilly and Company
  • 6. Ferring B.V.
  • 7. GlaxoSmithKline Plc.
  • 8. Horizon Therapeutics plc
  • 9. Johnson & Johnson Private Limited
  • 10. Medivir AB
  • 11. Merck Sharp & Dohme Corp.
  • 12. Novartis AG
  • 13. Pfizer, Inc.
  • 14. Regeneron Pharmaceuticals, Inc.
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. OSTEOARTHRITIS PAIN DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OSTEOARTHRITIS PAIN DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OSTEOARTHRITIS PAIN DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTERIODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023